<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00697281</url>
  </required_header>
  <id_info>
    <org_study_id>OC000459/010/07</org_study_id>
    <nct_id>NCT00697281</nct_id>
  </id_info>
  <brief_title>OC000459 Dose Finding Study in Hay Fever Sufferers.</brief_title>
  <official_title>A Dose Finding Study Of The Effects Of OC000459 On Responses To Allergen Challenge In The Vienna Chamber In Subjects Known To Suffer From Grass Pollen Induced Allergic Rhinitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oxagen Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oxagen Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate a range of dose levels for efficacy in the&#xD;
      control of symptoms of allergic rhinitis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomised, double blind, placebo controlled, parallel group evaluation of&#xD;
      OC000459 given orally for eight days. Four dose levels will be studied and compared to&#xD;
      placebo. They will be studied in treatment groups of 18 to 21 subjects. The placebo group&#xD;
      will also consist of 18 to 21 subjects. There will be a screening period of up to six weeks.&#xD;
      There will be a follow up one to three weeks after the last dose of study drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total nasal symptom score (TNSS)</measure>
    <time_frame>After 8 days of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other symptom scores of allergic rhinitis</measure>
    <time_frame>After 8 days of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OC000459</intervention_name>
    <description>Tablets twice daily for 8 days&#xD;
Dose level 1</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OC000459</intervention_name>
    <description>Tablets twice daily for 8 days&#xD;
Dose level 2</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OC000459</intervention_name>
    <description>Tablets twice daily for 8 days&#xD;
Dose level 3</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OC000459</intervention_name>
    <description>Tablets twice daily for 8 days&#xD;
Dose level 4</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets twice daily for 8 days&#xD;
Dose level 5</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females aged 18 to 50 years with a history of symptoms of grass pollen&#xD;
             related allergic rhinitis within the previous two years.&#xD;
&#xD;
          -  Females of childbearing potential (i.e. having had a menstrual period within two years&#xD;
             prior to the date of screening) must practise two forms of contraception and must have&#xD;
             a negative pregnancy test (blood or urine) at screening.&#xD;
&#xD;
          -  Acceptable contraception includes the use of TWO of the following:&#xD;
&#xD;
               -  oral contraception (i.e. the Pill);&#xD;
&#xD;
               -  intrauterine device (an IUD or 'Coil');&#xD;
&#xD;
               -  barrier contraception (i.e. condoms or diaphragm/cap);&#xD;
&#xD;
               -  transdermal patch&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical conditions likely to affect the outcome of the study.&#xD;
&#xD;
          -  Nasal conditions likely to affect the outcome of the study, i.e. nasal septal&#xD;
             perforations, nasal polyps, sinus disease, chronic nasal obstruction, or other nasal&#xD;
             diseases as determined by the principal investigator or designee.&#xD;
&#xD;
          -  Presence of any respiratory disease other than a history of mild stable asthma not&#xD;
             requiring treatment and associated with normal lung function (defined as FEV1 â‰¥ 90%&#xD;
             predicted for height and age).&#xD;
&#xD;
          -  Immunotherapy treatment course in the past 28 days&#xD;
&#xD;
          -  Use of inhaled or local corticosteroids in the past 28 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Univ Prof. Dr. Friedrich Horak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allergie Zentrum Wien West</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergie Zentrum Wien West, Vienna Challenge Chamber</name>
      <address>
        <city>Vienna</city>
        <zip>1150 VIENNA</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>June 11, 2008</study_first_submitted>
  <study_first_submitted_qc>June 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2008</study_first_posted>
  <last_update_submitted>February 23, 2009</last_update_submitted>
  <last_update_submitted_qc>February 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr C Mike Perkins</name_title>
    <organization>Oxagen Ltd</organization>
  </responsible_party>
  <keyword>allergic rhinitis</keyword>
  <keyword>human</keyword>
  <keyword>clinical trial</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>challenge test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indoleacetic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

